EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

LINE-1 266/97 and ALU 260/111 Copy Number Ratios in Circulating Cell-Free DNA in Plasma as Potential Biomarkers for the Detection of Prostate Cancer: A Pilot Case-Control Study

Domenico Tierno, Nicola Pavan iD, Fabiola Giudici iD, Gabriele Grassi iD, Eleonora Valeri, Fabrizio Zanconati, Fabio Traunero iD, Giovanni Liguori iD, Bruna Scaggiante iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26188862 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Domenico Tierno und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Health Science, University of Trieste, 34129 Trieste, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Cell-Free Nucleic Acids, Biomarkers, Tumor, Alu Elements. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is the second most common cancer and the fourth leading cause of cancer death in men worldwide. PSA screening for PCa diagnosis is not disease-specific; the discovery of novel and efficient biomarkers is therefore recommended. The concentration and integrity of circulating cell-free DNA (ccfDNA) in the blood of PCa patients could represent innovative and more specific tools for the clinical management of PCa. Digital droplet PCR (ddPCR) was used to determine the copy number ratio of ALU 260/111 bp and LINE-1 266/97 bp in the plasma of a cohort of 40 PCa and 18 BPH patients in a blinded prospective study. The amount of ccfDNA in the plasma of PCa and BPH patients was calculated from the EEF1A2 and ESR1 gene copy numbers. The ALU 260/111 and LINE-1 266/97 copy number ratios were significantly lower in the plasma of PCa patients compared to benign prostatic hyperplasia (BPH) ones (p-value; ALU 260/111: 0.006; LINE-1 266/97: 0.037). The area under the curve (AUC) indicated a good accuracy of two ratios and their product (ALU 260/111 * LINE 266/97, A*L) in discriminating PCa patients from BPH ones (AUC; ALU 260/111: 0.72; LINE-1 266/97: 0.67; A*L: 0.76). The ccfDNA concentration measured by EEF1A2 and ESR1 targets was significantly higher in the plasma of PCa patients compared to BPH patients, (p-value: EEF1A2, 0.017; ESR1, 0.024). The pilot ddPCR analysis of the ALU 260/111 and LINE-1 266/97 ratios in plasma indicates a new, reproducible and specific method for improving the early diagnosis of PCa. Further studies on larger cohorts are needed to confirm the results and clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCell-Free Nucleic AcidsBiomarkers, TumorAlu ElementsLong Interspersed Nucleotide ElementsHumansMalePilot ProjectsAgedCase-Control StudiesMiddle AgedProstatic HyperplasiaDNA Copy Number VariationsProspective Studies

Stichwörter der Autor:innen

ALULINE-1cfDIcfDNAcfDNA integritycopy numberddPCRliquid biopsyprostate cancer

Substanzen

Cell-Free Nucleic AcidsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine, Surgery and Health Science, University of Trieste, 34129 Trieste, Italy.
  • Department of Surgical, Oncological, and Oral Sciences, University of Palermo, 90127 Palermo, Italy.
  • Cancer Epidemiologic Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 33081 Aviano, Italy.
  • Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
  • Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy.

ORCID-Profile: Nicola Pavan, Fabiola Giudici, Gabriele Grassi, Fabio Traunero, Giovanni Liguori, Bruna Scaggiante

Zitieren

APA

Tierno, D., Pavan, N., Giudici, F., Grassi, G., Valeri, E., Zanconati, F., Traunero, F., Liguori, G., & Scaggiante, B. (2025). LINE-1 266/97 and ALU 260/111 Copy Number Ratios in Circulating Cell-Free DNA in Plasma as Potential Biomarkers for the Detection of Prostate Cancer: A Pilot Case-Control Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188862

Vancouver

Tierno D, Pavan N, Giudici F, Grassi G, Valeri E, Zanconati F, et al. LINE-1 266/97 and ALU 260/111 Copy Number Ratios in Circulating Cell-Free DNA in Plasma as Potential Biomarkers for the Detection of Prostate Cancer: A Pilot Case-Control Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188862

BibTeX
@article{Tierno2025,
  author = {Tierno, Domenico and Pavan, Nicola and Giudici, Fabiola and Grassi, Gabriele and Valeri, Eleonora and Zanconati, Fabrizio and Traunero, Fabio and Liguori, Giovanni and Scaggiante, Bruna},
  title = {LINE-1 266/97 and ALU 260/111 Copy Number Ratios in Circulating Cell-Free DNA in Plasma as Potential Biomarkers for the Detection of Prostate Cancer: A Pilot Case-Control Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26188862}
}
Kostenlos starten →